Dexlansoprazole MR for Symptomatic Non-Erosive GERD

Phase 3, randomised, double-blind trial of dexlansoprazole in Non-erosive Gastroesophageal Reflux Disease (NERD) (3 arms), sponsored by Takeda. Primary endpoints: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median at 4 weeks and Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean at 4 weeks. Started Dec 2005; status: completed.